Goldman, Sachs

Goldman Sachs Emerges as Dominant Force in XRP ETF Market

17.03.2026 - 00:18:15 | boerse-global.de

Goldman Sachs holds $153.8M in spot XRP ETFs, while XRP Ledger hits 3M daily transactions. Analysis reveals diverging trends of institutional investment and token price decline.

Goldman Sachs Emerges as Dominant Force in XRP ETF Market - Foto: über boerse-global.de

Recent regulatory filings reveal that Goldman Sachs has established itself as the single largest institutional holder of spot XRP exchange-traded funds, commanding a position valued at approximately $153.8 million. This substantial investment represents nearly 73% of all reported institutional holdings among the top thirty fund holders. This accumulation of institutional interest coincides with a separate, significant milestone: the daily transaction count on the XRP Ledger has surged to three million, marking a threefold increase. These two developments present a complex picture of contrasting market signals.

Diverging Trends: Institutional Accumulation Amid Price Decline

The launch of spot XRP ETFs followed the November 2025 settlement of the protracted legal battle between Ripple and the U.S. Securities and Exchange Commission. Since their introduction, these financial products have attracted net inflows of $1.4 billion, with assets under management climbing to roughly $1.44 billion by early March 2026. Notably, net outflows have occurred on only nine trading days since inception.

However, analysis from Bloomberg ETF experts James Seyffart and Eric Balchunas suggests that an estimated 84% of ETF holdings belong to retail investors, whose positions fall below the mandatory 13F reporting threshold. Consequently, the publicly available institutional data captures just a fraction of the actual investor base.

The timing of Goldman Sachs' position-building is particularly striking. As the financial giant increased its exposure, the value of the XRP token itself experienced a significant downturn. From a peak near $2.40 in early January 2026, the cryptocurrency's price fell by over 40%. XRP currently trades around $1.51, a level substantially below its 200-day moving average of $2.15, highlighting a pronounced longer-term technical weakness.

Network Expansion and a Contentious Buyback

Amid the price volatility, the underlying XRP Ledger network demonstrates tangible growth. The total value of real-world assets tokenized on the ledger has reached $474.6 million, with a represented notional volume approaching $1.5 billion. A structurally significant development is the inclusion of Ripple Prime—the rebranded broker Hidden Road, which Ripple acquired for $1.25 billion in April 2025—into the Depository Trust & Clearing Corporation’s (DTCC) NSCC directory. This integration enables Ripple Prime to settle institutional post-trade volumes directly via the XRP Ledger, tapping into the DTCC's system that processes quadrillions of dollars in transactions annually.

Should investors sell immediately? Or is it worth buying XRP?

Less universally applauded is Ripple's announced $750 million share buyback program, which values the company at about $50 billion. Critics contend that this corporate action exclusively benefits company shareholders and is partially funded by sales from the XRP escrow, offering no direct utility to holders of the XRP token.

Roadmap and Price Trajectories

Ripple's technical development agenda for 2026 is squarely focused on institutional adoption. Key initiatives include Confidential Multi-Purpose Tokens for collateral management, a native lending protocol for on-chain credit markets, and formal verification processes for core ledger components. These upgrades are designed to strengthen the infrastructure for regulated financial applications.

In terms of price forecasts, Standard Chartered has revised its XRP price target upward to $2.80. The broader institutional consensus for the end of 2026 suggests a wide range between $3.00 and $8.00, reflecting the prevailing market uncertainty. CEO Brad Garlinghouse has labeled 2026 a "pivotal year" for Ripple, a stance supported by a series of strategic acquisitions across payments processing, custody, and liquidity management.

Ad

XRP Stock: New Analysis - 17 March

Fresh XRP information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated XRP analysis...

So schätzen die Börsenprofis Goldman Aktien ein!

<b>So schätzen die Börsenprofis Goldman Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
3604058040CR | GOLDMAN | boerse | 68697055 |

Weitere Meldungen

ANALYSE-FLASH: Goldman senkt Ziel für Henkel auf 70 Euro - 'Sell' Die US-Investmentbank Goldman Sachs hat das Kursziel für Henkel DE0006048432 vor Quartalszahlen von 73 auf 70 Euro gesenkt und die Einstufung auf "Sell" belassen. (Boerse, 02.04.2026 - 12:35) weiterlesen...

ANALYSE-FLASH: Goldman hebt Ziel für Evonik auf 20 Euro - 'Buy' Die US-Investmentbank Goldman Sachs hat das Kursziel für Evonik DE000EVNK013 vor Quartalszahlen von 18 auf 20 Euro angehoben und die Einstufung auf "Buy" belassen. (Boerse, 02.04.2026 - 11:20) weiterlesen...

ANALYSE-FLASH: Goldman hebt Rheinmetall auf 'European Conviction List' - 'Buy' Die US-Investmentbank Goldman Sachs hat die Rheinmetall-Aktie DE0007030009 in die "European Conviction List" für besonders aussichtsreiche Werte aufgenommen. (Boerse, 01.04.2026 - 19:05) weiterlesen...

AKTIE IM FOKUS: Goldman Sachs treibt kräftige Rheinmetall-Erholung voran Die Aktie von Rheinmetall DE0007030009 hat sich am Mittwoch im freundlichen Gesamtmarkt weiter von ihrem am Montag erreichten Elf-Monats-Tief nach oben hin abgesetzt. (Boerse, 01.04.2026 - 16:51) weiterlesen...

ANALYSE-FLASH: Goldman senkt Ziel für Lanxess auf 21 Euro - 'Neutral' Die US-Investmentbank Goldman Sachs hat das Kursziel für Lanxess DE0005470405 vor Zahlen zum ersten Quartal von 23 auf 21 Euro gesenkt und die Einstufung auf "Neutral" belassen. (Boerse, 01.04.2026 - 12:34) weiterlesen...

ANALYSE-FLASH: Goldman hebt Sartorius Stedim Biotech auf 'Buy' - Ziel gesenkt Die US-Investmentbank Goldman Sachs hat das Kursziel für Sartorius Stedim FR0013154002 von 235 auf 214 Euro gesenkt, die Aktien aber von "Neutral" auf "Buy" hochgestuft. (Boerse, 30.03.2026 - 09:04) weiterlesen...